Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Otolaryngol Head Neck Surg. 2024 Oct;171(4):1245-1249. doi: 10.1002/ohn.850. Epub 2024 Jun 17.
Sinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty-four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One-year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%-60.9%), with a median survival of 2.8 years (95% CI: 2.0-5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12-0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02). LEVEL OF EVIDENCE: Level IV.
鼻腔鼻窦黑色素瘤（SNMM）是一种预后不良且复发率高的罕见恶性肿瘤。对于那些复发的患者，生存情况不容乐观。免疫疗法是一个新兴的研究领域；然而，关于复发的 SNMM 患者免疫治疗结果的数据却很少。我们报告了复发的 SNMM 患者中接受免疫治疗的结果，这些患者的复发部位是远处还是非远处。
确定了 54 例复发的 SNMM 患者，其中 31 例（57.4%）有远处复发。复发后 1 年的总生存率（OS）为 47.5%（95%置信区间[CI]：34.0%-60.9%），中位生存时间为 2.8 年（95%CI：2.0-5.3）。在远处复发的患者中，与未接受免疫治疗的患者相比，接受免疫治疗的患者 OS 更好（风险比[HR] = 0.29 [95% CI: 0.12-0.68]，P = .004）。然而，对于远处复发（n = 23）的患者，接受免疫治疗（n = 6）的患者 OS 较未接受免疫治疗的患者更差（HR = 4.76 [95% CI: 1.36, 15.89]，P = .02）。
IV 级。
Zotero 插件